Researcher
Gil Awada
- Keywords:Medicine
- Disciplines:Natural sciences, Engineering and technology, Social sciences
Affiliations
- Medical Oncology (Department)
Member
From1 Sep 2023 → Today - Laboratory for Medical and Molecular Oncology (Research group)
Member
From22 Mar 2021 → Today - Clinical sciences (Department)
Member
From15 Nov 2023 → Today - Clinical sciences (Department)
Member
From15 Nov 2023 → 15 Nov 2023 - Medical Oncology (Department)
Member
From1 Nov 2021 → 31 Jul 2023 - Internal medicine (Department)
Member
From1 Sep 2021 → 31 Oct 2021 - Medical Oncology (Department)
Member
From1 Aug 2021 → 31 Aug 2021 - Clinical sciences (Department)
Member
From8 Apr 2019 → 31 Jul 2021 - Clinical sciences (Department)
Member
From1 Oct 2017 → 31 Jul 2021 - Faculty of Medicine and Pharmacy (Faculty)
Member
From13 Jul 2017 → 18 Jun 2021 - Internal medicine (Department)
Member
From1 Aug 2016 → 31 Jul 2021 - Faculty of Medicine and Pharmacy (Faculty)
Member
From4 Oct 2015 → 27 Apr 2023 - Faculty of Medicine and Pharmacy (Faculty)
Member
From1 Aug 2011 → 24 Jun 2015
Publications
21 - 30 of 37
- Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study(2020)
Authors: Anne Rogiers, Christophe Leys, Jennifer De Cremer, Gil Awada, Adrian Schembri, Peter Theuns, Mark De Ridder, B Neyns
Pages: 3267-3278 - Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1(2020)
Authors: Gil Awada, Daphne Serruys, Julia Katharina Schwarze, Lien Van De Voorde, Johnny Duerinck, B Neyns
Pages: 1031–1036 - Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy(2019)
Authors: Teofila Seremet, Yanina Jansen, Simon Planken, Hassan Njimi, Melanie Delaunoy, Hakim El Housni, Gil Awada, Julia Katharina Schwarze, Marleen Keyaerts, Hendrik Everaert, et al.
- Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors(2019)
Authors: Anne Rogiers, Annelies Boekhout, Julia Katharina Schwarze, Gil Awada, Christian Blank, B Neyns
- Supportieve zorg bij de behandeling met immuuncheckpointinhibitoren(2019)
Authors: Gil Awada, Anne Rogiers, B Neyns
Pages: 39-50 - Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition(2018)
Authors: Gil Awada, Teofila Seremet, Karel Fostier, Hendrik Everaert, B Neyns
Pages: 2156-2158 - Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer(2018)
Authors: Gil Awada, Jean Klastersky
Pages: 98-104 - Long-term survival in immunotherapy treated patients with unresectable advanced melanoma(2018)
Authors: B Neyns, Gil Awada, Anne Rogiers
Pages: 3-10 - Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients(2017)
Authors: Gil Awada, Evandro de Azambuja, Ahmad Awada
Pages: 1205-1215 - The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.(2017)
Authors: Hampig Raphael Kourie, Gil Awada, Ahmad Awada
Pages: 647-657